Follow us on Twitter
twitter icon@FreshPatents

Kinetics patents

Bulk PDF Downloads
      

This page is updated frequently with new Kinetics-related patent applications.




 Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphilphilic molecules patent thumbnailnew patent Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphilphilic molecules
Aspects of the invention relate to methods for measuring the binding constant of a lipophilic or amphiphilic molecule acceptor for a lipophilic or amphiphilic molecule. Methods involve rapid, cell-free competition assays including a labeled lipophilic or amphiphilic molecule and nanoparticle..
Northwestern University


 Calcium-magnesium-alumino-silicate resistant thermal barrier coatings patent thumbnailnew patent Calcium-magnesium-alumino-silicate resistant thermal barrier coatings
A method for forming a coating system on a component includes depositing a reactive layer with predetermined cmas reaction kinetics on at least a portion of a thermal baffler coating. The method also includes activating the reactive layer with a scanning laser.
United Technologies Corporation


 Sorbic acid ester containing coatings composition patent thumbnailnew patent Sorbic acid ester containing coatings composition
The present invention is a composition comprising a solution or a dispersion of polymer particles, a sorbate ester or sorbamide curing agent, and a cure modulating additive for the curing agent. The curing agent is a sorbic acid ester or a sorbamide and the cure modulating agent is a reagent capable of accelerating or attenuating the rate of cure of the curing agent.
Rohm And Haas Company


 Disubstituted maleic anhydrides with altered kinetics of ring closure patent thumbnailnew patent Disubstituted maleic anhydrides with altered kinetics of ring closure
We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules.
Arrowhead Madison Inc.


 Spraying device for quickly forming gas hydrates patent thumbnailnew patent Spraying device for quickly forming gas hydrates
A spraying device for quickly forming gas hydrates, includes a stable gas supply system, a saturated solution preparation system, a gas-liquid mixed sprayer, a temperature control system and a data collecting and processing system. Pressure atomization is achieved at a high atomization speed and the atomized fog drops are uniformly distributed within a scale range of 5-10 microns to form a gas-in-water contact mode, so as to effectively increase a gas-water contact superficial area and significantly shorten the induction time of forming the gas hydrates.
Guangzhou Institute Of Energy Conversion, Chinese Academy Of Sciences


 Polymerase compositions and methods patent thumbnailPolymerase compositions and methods
Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions.
Life Technologies Corporation


 Extensible infusion devices and related methods patent thumbnailExtensible infusion devices and related methods
Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver fluid to a user in accordance with an operating mode involves identifying a fluid type associated with the fluid currently onboard the infusion device from among a plurality of possible fluid types that is different from a previous type of fluid previously onboard the infusion device.
Medtronic Minimed, Inc.


 Vortex-induced silk fibroin gelation for encapsulation and delivery patent thumbnailVortex-induced silk fibroin gelation for encapsulation and delivery
The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of β-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned, enabling the use of these approach for precise control of silk self-assembly, both spatially and temporally.
Trustees Of Tufts College


 High performance knee prosthesis patent thumbnailHigh performance knee prosthesis
Knee prostheses featuring components that more faithfully replicate the structure and function of the human knee joint in order to provide, among other benefits: greater flexion of the knee in a more natural way by promoting or at least accommodating internal tibial rotation in a controlled way, replication of the natural screw home mechanism, and controlled articulation of the tibia and femur respective to each other in a more natural way. In a preferred embodiment, such prostheses include an insert component disposed between a femoral component and a tibial component, the insert component preferably featuring among other things a reversely contoured posterolateral bearing surface that helps impart internal rotation to the tibia as the knee flexes.
The Trustees Of The University Of Pennsylvania


 Implantable devices and methods for evaluation of active agents patent thumbnailImplantable devices and methods for evaluation of active agents
Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure and contain one or more active agents, alone or in combination, in one or more dosages and/or release pharmacokinetics.
Massachusetts Institute Of Technology


Tunable covalently crosslinked hydrogels and methods of making the same


The present invention provides, among other things, a elastomeric biomaterial having enzymatically cross-linked amino acid phenolic side chains to generate highly elastic hydrogels. Materials are characterized by tunable mechanical properties, gelation kinetics and swelling properties of these new protein polymers.
Trustees Of Tufts College


Environmentally sensitive compositions


An environmentally sensitive membrane binding polypeptide, ph (low)-sensitive membrane peptide (phlip) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.. .
Yale University


Anti-c5 antibodies having improved pharmacokinetics


The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human..
Alexion Pharmaceuticals, Inc.


Designed repeat proteins binding to serum albumin


New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin..
Molecular Partners Ag


Evolution of bond-forming enzymes


Strategies, systems, methods, reagents, and kits for the directed evolution of bond-forming enzymes are provided herein. Evolution products, for example, evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are also provided herein, as are methods for using such evolved bond-forming enzymes.
President And Fellows Of Harvard College


Antibodies with modified affinity to fcrn that promote antigen clearance


The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human fcrn-binding activity at the plasma ph and a lower antigen-binding activity at the early endosomal ph than at the plasma ph; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can be facilitated by administering such an antibody; and antibody pharmacokinetics can be improved by using such antibodies.. .

Voxel-resolution myocardial blood flow analysis


A myocardial blood flow analysis scan includes incorporating a pharmacological kinetic model with the standard factor analysis model where each time activity curve is assumed to be a linear combination of factor curves. Pharmacological kinetics based factor analysis of dynamic structures (k-fads-ii) model can be applied, whereby estimating factor curves in the myocardium can be physiologically meaningful is provided.
Howard University


Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
Auspex Pharmaceuticals, Inc.


Pnictide containing catalysts for electrochemical conversion reactions and methods of use


This patent application describes graphitic carbon nitride materials that are useful in electrochemical cells such as lithium-sulfur batteries. Also disclosed are lithium-sulfur batteries designed to incorporate these materials and methods of manufacturing the same.
The Regents Of The University Of California


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Pharmaceutical compositions comprising meloxicam


Disclosed herein are compositions comprising an nsaid such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the nsaid for the treatment of conditions such as pain..
Antecip Bioventures Ii Llc


Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
Auspex Pharmaceuticals, Inc.


Method of providing sustained analgesia with buprenorphine


A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.. .
Purdue Pharma L.p.


Adsorption of immunopotentiators to insoluble metal salts


Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption.
Glaxosmithkline Biologicals Sa


Formulations and methods for treatment of metabolic syndrome


Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory and pancreatic beta-cell centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc


Method and system for selecting drug on basis of individual protein damage information for preventing side effects of drug


The present invention relates to a method and a system for selecting a drug customized on the basis of individual protein information by using individual genome sequences. The method and the system of the present invention can predict the individual side effects or danger of a certain drug by analyzing the sequence of the exon region of a gene encoding various proteins involved in the pharmacokinetics or pharmacodynamics of a predetermined drug or drug group, and have high reliability and are widely applicable and universal..
Cipherome, Inc.


Componential analyzer, drug efficacy analyzer, and analysis method


Application of the present invention enables quantification of fractions of candidate pharmaceutical compounds (a parent compound and its metabolites), one excreted to the basolateral (basal/basolateral)-side via transporters and by diffusion, one excreted to the lumen (apical)-side, and one remained in the cells. This enables determination of the total amount of the administered candidate pharmaceutical compounds and the distribution ratio of the fractions.
Hitachi High-technologies Corporation


Evolved sortases and use thereof


Evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are provided herein, for example evolved sortases that bind recognitions motifs comprising a laxt or lpxs sequence. Also provided are methods (e.g., orthogonal transpeptidation and diagnostics methods) for using such sortases.
President And Fellows Of Harvard College


Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders


The subject invention relates to improved tocopheryl quinone derivatives and tocopherol derivatives having improved pharmacokinetics in vivo that can, in some embodiments, be useful in the treatment of lysosomal storage disorders, restoration of normal mitochondrial atp production, modulation of intracellular calcium ion concentration and other treatments or therapies. The tocopheryl quinone derivatives and tocopherol derivatives have side chains that have terminally halogenated carbon atoms..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Novel aromatic compound and use thereof


[wherein each substituent is as defined in the description], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or to treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.. .

Implantable devices and methods for the evaluation of active agents


Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure.
Kibur Medical, Inc.


New formulation methodology for distortional thermosets


And a diamine curing agent. The resultant distortional thermoset compositions possess superior out-life requirements and advantageous reaction kinetics for preparing prepreg compositions and materials..

Dosage form incorporating an amorphous drug solid solution


The dissolution of active pharmaceutical ingredients in polymeric melts plays an important role in the manufacturing of drugs that use polymers as excipients. The dissolution kinetics is essential for designing the processing equipment, describing the operating conditions, and defining material properties, for example, the appropriate api-polymer(s) pair.

Using kinetic cyclic voltammetry to evaluate analyte kinetics and concentrations


Materials and methods for using kinetic cyclic voltammetry to measure analyte levels and assess analyte kinetics.. .
Mayo Foundation For Medical Education And Research


Genetically modified rat models for pharmacokinetics


The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the slc7a11 (nc_005101.2) gene, the abcb1 (nc_005103.2) gene, etc.

Simulation of endogenous and exogenous glucose/insulin/glucagon interplay in type 1 diabetic patients


A simulator for in-silico testing of type 1 diabetes patients uses a model that puts in relation plasma concentrations, i.e., glucose g and insulin /, with glucose fluxes, i.e. Endogenous glucose production (egp), glucose rate of appearance (ra), glucose utilization by the tissues (u), renal extraction (e), and insulin fluxes, i.e., rate of insulin appearance from the subcutaneous tissues (sc) and insulin degradation (d).
University Of Virginia Patent Foundation


Kinetics biomarkers for neurodegeneration


The present invention relates to novel diagnostic, prognostic, predictive and pharmacodynamic properties with regard to amyotrophic lateral sclerosis (als) and/or parkinson's disease (pd) with and without dementia components. The methods described herein will prove very useful in the development of diagnostic as well as treatment strategies for patients with amyotrophic lateral sclerosis (als) and/or parkinson's disease (pd)..
Kinemed, Inc.


In situ chemical transformation and ionization of inorganic perchlorates on surfaces


A method for providing in situ chemical transformation and ionization of a portion (e.g., inorganic oxidizer) of a sample via an analyte detection system is disclosed herein. The method includes introducing a gas into an ionization source of the analyte detection system via an inlet.
Smiths Detection Montreal Inc.


Antibody constant region variant


By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production.
Chugai Seiyaku Kabushiki Kaisha


Controlling of sintering kinetics of oxide ceramics


The invention relates to multi-layer oxide ceramic bodies and in particular to presintered multi-layer oxide ceramic blanks and oxide ceramic green bodies suitable for dental applications. These bodies can be thermally densified by further sintering without distortion and are thus particularly suitable for the manufacture of dental restorations.
Ivoclar Vivadent Ag


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Device and determining reaction kinetics


Or to derive a temperature-dependent activation energy if that is more appropriate for the chemical species of interest.. .

Device and rapid linker mediated label-based immunoassays


A method and system is provided which uses cleavable linkers to detect an analyte in an immunoassay. The use of linkers in elisa and similar immunoassay protocols allows for a reduction in wash steps, incubation time, and potential for user error.

Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production


The invention provides a herpes simplex virus (hsv) vector that does not express toxic hsv genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes icp0, icp4, tcp22, tcp27 and tcp47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


Small molecule-dependent inteins and uses thereof


Elucidating the function of proteins in mammalian cells is particularly challenging due to the inherent complexity of these systems. Methods to study protein function in living cells ideally perturb the activity of only the protein of interest but otherwise maintain the natural state of the host cell or organism.
President And Fellows Of Harvard College


Apparatus for analyzing ion kinetics in dielectrics


An apparatus for analyzing ion kinetics in a dielectric probe structure includes an ion reservoir abutting the dielectric probe structure and configured to supply mobile ions to the dielectric probe structure, a capacitor structure configured to generate an electric field in the dielectric probe structure along a vertical direction, and an electrode structure configured to generate an electrophoretic force on mobile ions in the dielectric probe structure along a lateral direction. A method for analyzing ion kinetics in the dielectric probe structure of the apparatus is also provided..
Infineon Technologies Ag


Nucleic acid detection by oligonucleotide probes cleaved by both exonuclease and endonuclease


Disclosed is a method in the fields of biochemistry and molecular biology. The method is related to improve cleavage kinetics of labeled oligonucleotide probes and, consequently, increases signal-to-noise ratio in detecting nucleic acids..
Samsung Techwin Co., Ltd.


Heparosan/therapeutic prodrug complexes and methods of making and using same


Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or complexation vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. In certain non-limiting embodiments, the use of heparosan is complexed with anti-cancer drugs and the like, thus forming a prodrug for the purposes of increasing efficacy and reducing side effects compared to the parental drug alone..
The Board Of Regents Of The University Of Oklahoma


Anti-c5 antibodies having improved pharmacokinetics


The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human..

Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug


The present invention relates to imidazole derivatives of formula (i), and pharmaceutically acceptable salts thereof, wherein a, b, y, r1 and r2 are as defined herein. The present invention also relates to compositions comprising at least one imidazole derivative, and methods of using the imidazole derivatives for inhibiting cyp450 3a.

Tamper resistant dosage form comprising inorganic salt


The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 n, said dosage form containing a pharmacologically active ingredient (a); an inorganic salt (b); and a polyalkylene oxide (c) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (c) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (a) is present in a controlled-release matrix comprising the inorganic salt (b) and the polyalkylene oxide (c) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (a) from said matrix comprises at least a time interval during which the release follows zero order kinetics.. .

Timed, pulsatile release systems


A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target pk (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating.

Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces


The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers.

Inhibitors of inv(16) leukemia


This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
University Of Virginia Patent Foundation


Application of enrofloxacin salt in preparation of oral preparation for pigs


The invention discloses application of an enrofloxacin salt in preparation of an oral preparation for pigs. The enrofloxacin salt is at least one of salts formed by enrofloxacin and metal ions, and the metal ions are zinc, copper, calcium, magnesium, iron, cobalt, manganese, chromium, silver or nickel.
Guangzhou Insighter Biotechnology Co., Ltd.


Method to enhance exploration, development and production of hydrocarbons using multiply substituted isotopologue geochemistry, basin modeling and molecular kinetics


A method and system are described that may be used for exploration, production and development of hydrocarbons. The method and system may include analyzing a sample for a geochemical signature, wherein the geochemical signature includes a multiply substituted isotopologue signature and/or a position specific isotope signature.

Method to enhance exploration, development and production of hydrocarbons using multiply substituted isotopologue geochemistry, basin modeling and molecular kinetics


A method and system are described that may be used for exploration, production and development of hydrocarbons. The method and system may include analyzing a sample for a geochemical signature, wherein the geochemical signature includes a multiply substituted isotopologue signature and/or a position specific isotope signature.

Metabolic evolution of escherichia coli strains that produce organic acids


This invention relates to the metabolic evolution of a microbial organism previously optimized for producing an organic acid in commercially significant quantities under fermentative conditions using a hexose sugar as sole source of carbon in a minimal mineral medium. As a result of this metabolic evolution, the microbial organism acquires the ability to use pentose sugars derived from cellulosic materials for its growth while retaining the original growth kinetics, the rate of organic acid production and the ability to use hexose sugars as a source of carbon.
Myriant Corporation


Human protein scaffold with controlled serum pharmacokinetics


This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises domain iii, domain iiia, or domain iiib of human serum albumin or a polypeptide having substantial sequence identity to the domain iii, the domain iiia, or the domain iiib; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct.
The Regents Of The University Of California


Metal complexes and fluorination thereof


A method of labelling biological molecules with 18f, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (h-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation.
University Of Southampton


Method to manufacture pla using a new polymerization catalyst


The invention relates to a method for manufacturing polylactide, comprising the steps of mixing lactide and a metal-coordination compound as polymerization catalyst to obtain a reaction mixture, polymerizing the lactide in liquid phase at a temperature of at least 150° c. To form polylactide in liquid phase and allowing the polylactide to solidify, characterized in that the polymerization catalyst comprises a metal-ligand coordination compound whereby the parent ligand answers the formula (i), whereby r represents an h atom, an aliphatic group, a halide atom or a nitro group and the metal is at least one of zr and hf.
Purac Biochem Bv


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Synthesis and molecular weight control of aliphatic polyester diols


The synthesis of certain polyester diols (peds) is disclosed. This application also discloses the purification and polymerization kinetics of lipid based peds.
Trent University


Metal complexes and their fluorination


A method of labelling biological molecules with 18f, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (h-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation.
University Of Southampton


Salts of an epidermal growth factor receptor kinase inhibitor


The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of egfr kinases and which exhibits desirable characteristics for the same. Examples include hydrobromide and bis-besylate salts of n-(3-(2-(4-(4-acerylpiperazin-1-yl)-2-methoxyphenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide).
Clovis Oncology, Inc.


Pharmaceutical compositions of tamsulosin or salts thereof


The present invention relates to pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core.
Wockhardt Limited


Retrospective retrofitting method to generate a continuous glucose concentration profile by exploiting continuous glucose monitoring sensor data and blood glucose measurements


Continuous glucose monitoring (cgm) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, cgm readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g.
UniversitÀ Degli Studi Di Padova Area Trasfermiento Di Tecnologia


Microfluidic chip-based, universal coagulation assay


A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents.
Perosphere Inc.


Rapid allergy testing method


The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient.

Antibodies with modified isoelectric points and immunofiltering


The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. Increased serum half-life in vivo..
Xencor, Inc.


Metabolic syndrome treatment


Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc


Methods for treating psoriasis using an anti-il-23 antibody


The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human il-23 while sparing il-12.
Amgen Inc.


Albumin variants binding to fcrn


The invention relates to methods of identifying albumin variants having improved pharmacokinetics, albumin variants having improved pharmacokinetics, and therapeutic uses of albumin variants having improved pharmacokinetics.. .
Eleven Biotherapeutics, Inc.


Method and device for controlling drug pharmacokinetics


Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.. .
Becton, Dickinson And Company


Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases


The invention relates to the discovery of novel soluble neutral active hyaluronidase glycoproteins (shasegps), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
Halozyme, Inc.


Metal-air cell with performance enhancing additive


Systems and methods drawn to an electrochemical cell comprising a low temperature ionic liquid comprising positive ions and negative ions and a performance enhancing additive added to the low temperature ionic liquid. The additive dissolves in the ionic liquid to form cations, which are coordinated with one or more negative ions forming ion complexes.
Arizona Board Of Regents Acting For And On Behalf Of Arizona State University


Methods for processing titanium alloys


Methods of refining the grain size of a titanium alloy workpiece include beta annealing the workpiece, cooling the beta annealed workpiece to a temperature below the beta transus temperature of the titanium alloy, and high strain rate multi-axis forging the workpiece. High strain rate multi-axis forging is employed until a total strain of at least 1 is achieved in the titanium alloy workpiece, or until a total strain of at least 1 and up to 3.5 is achieved in the titanium alloy workpiece.
Ati Properties, Inc.


Timed, pulsatile release systems


A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target pk (pharmocokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating.
Adare Pharmaceuticals, Inc.


Pharmacokinetic animal model


The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for hsa binding to the fcrn receptor in said animal. In the non-primate animal species, the binding affinity of wild type hsa to the native fcrn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native fcrn.
University Of Oslo


Methods for treating crohn's disease using an anti-il23 antibody


The invention relates to products and methods for treating crohn's disease. The products relate to antibodies that inhibit native human il-23 while sparing il-12.
Amgen Inc.


Polyoxazoline antibody drug conjugates


In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer adcs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (dar) of the antibody significantly beyond the currently available technology.
Serina Therapeutics, Inc.


Photocleavable deoxynucleotides with high-resolution control of deprotection kinetics


Provided herein are new classes of photocleavable deoxynucleotides that allow for more precise control over deprotection kinetics compared to previously described compounds. The compounds further feature more favorable solubility properties.
Ibis Biosciences, Inc.


Photoswitchable hdac inhibitors


This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of hdac having photoswitchable modulators of protein function with short thermal relaxation kinetics.
The General Hospital Corporation


Determination of physiological parameters of tissue from dynamic contrast-enhanced mr data


A method of determining microvascular architecture is disclosed. Dynamic contrast-enhanced magnetic resonance data acquired from a contrast agent administered to at least a part of a subject to be examined.
Koninklijke Philips N.v.


Novel cross-linked (bisphenol-s, formaldehyde, 1,6-hexadiamine) terpolymer for the adsorption of pb2+ ions from aqueous solutions


A cross-linked terpolymer (bsdf) obtained by polycondensation of bisphenol-s, formaldehyde and 1,6-diaminohexane. The terpolymer is highly efficient in eliminating lead ions from aqueous solutions.
King Fahd University Of Petroleum And Minerals


Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters


A timed release pharmaceutical composition comprising donepezil is provided wherein the single dose auc(14-22) of the said composition administered in the morning is about % to about 30% less than the single dose auc(2-10) of an immediate release composition of donepezil administered in the night, wherein both the compositions have equivalent dose of donepezil.. .
Lupin Limited


Nanopore sequencing methods


Methods are provided for sequencing of nucleic acid templates using nanopores. The rate of transport of the template nucleic acids through the nanopore is controlled using a polymerase enzyme having two slow kinetic steps.
Pacific Biosciences Of California, Inc.


Identifying modified bases using hemi-natural nucleic acids


Methods, compositions, and systems are provided for characterization of modified nucleic acids. Methods are provided for sequencing hemi-natural nucleic acids such as hemi-genomic dna, having two complementary strands, one a natural sequence and the other a synthetic sequence.
Pacific Bioscience Of California, Inc.


Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics


Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
Bayer Healthcare Llc


Crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations


The present invention relates to the crystalline mono mesylate monohydrate salt of n-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline n-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof..
Aicuris Gmbh & Co. Kg


Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters


A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° c., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.. .
Lupin Limited


Drug delivery system to increase bioavailability


Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.. .
Patheon Inc.


Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


Formulations of human tissue kallikrein-1 for parenteral delivery and related methods


Provided are high concentration compositions of tissue kallikrein-1 (klk1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human klk1 (rhklk1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof..
Diamedica Inc.




Kinetics topics:
  • Medical Device
  • Polypeptide
  • Nucleic Acid
  • Nucleic Acids
  • Specificity
  • Surfactant
  • Enhancement
  • Scattering
  • Electrolyte
  • Conductive Elements
  • Amplification
  • Red Blood Cell
  • Red Blood Cells
  • Antibodies
  • Luciferase


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.


    4.4053

    0

    469695 - 0 - 101